Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    ... AML) as documented by the presence of >20% myeloid blasts in the bone marrow Subjects must be 18 years of age and ...

    Clinical Trial last updated 06/13/2016 - 3:24pm.

  2. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... Disease status: remission or <10% bone marrow blasts Myelodysplasia Acute lymphoblastic leukemia Disease status: ...

    Clinical Trial last updated 06/06/2016 - 3:10pm.

  3. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... MDS/CMML (defined as ≥ 10% peripheral blood or marrow blasts and/or IPSS score ≥ 1.5) and relapsed or refractory to ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  4. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... Disease status: remission or <10% bone marrow blasts Myelodysplasia Acute lymphoblastic leukemia Disease status: ...

    Clinical Trial last updated 06/03/2016 - 2:45pm.

  5. Phase I, Dose Escalation Study of Decitabine

    ... (CR) following allo-HSCT ( bone marrow leukemic blasts less than 5% by morphology ), with high risk features ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  6. Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

    ... syndrome (MDS) (defined as having >/= 10% blasts in the bone marrow ) or patients with Chronic Myelomonocytic Leukemia (CMML) (having >/= 10% blasts in the bone marrow) may also be eligible after discussion with Principal ...

    Clinical Trial last updated 05/23/2016 - 3:37pm.

  7. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

    ... Must be in remission by morphology (<5% blasts ). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are ...

    Clinical Trial last updated 04/29/2016 - 10:06am.

  8. Allo HSCT Using RIC for Hematological Diseases

    ... be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a ... <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  9. Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

    ... adult patients with pathologically confirmed MDS (< 20% blasts in bone marrow , peripheral blood, or both) by World Health ...

    Clinical Trial last updated 05/03/2016 - 9:46am.

  10. Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

    ... or morphologic complete remission or MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating ...

    Clinical Trial last updated 05/02/2016 - 11:06am.